Pfizer/Esperion Deal Reunites Lipitor Team; $1.3 Bil. Buys Two HDL Agents
Executive Summary
Pfizer's $1.3 bil. acquisition of Esperion will reunite the Lipitor research team and give Pfizer two more chances to develop a novel mechanism anti-atherosclerotic agent
You may also be interested in...
Pfizer Deals With Incyte, NicOx Reflect Emphasis On External Partnerships
Pfizer appears to be closing out the year with a stepped-up emphasis on external partnerships through recent deals with Incyte and NicOx
Pfizer Deals With Incyte, NicOx Reflect Emphasis On External Partnerships
Pfizer appears to be closing out the year with a stepped-up emphasis on external partnerships through recent deals with Incyte and NicOx
Pfizer Torcetrapib Phase III Program Will Cost $800 Mil.
Pfizer is spending $800 mil. on the Phase III development program for the cholesterol agent torcetrapib, Worldwide Development President Joe Feczko, MD, said during a Nov. 30 analysts meeting in Groton, Conn